<DOC>
	<DOCNO>NCT00887978</DOCNO>
	<brief_summary>This study international , multi-center , randomize , double-blind , placebo-controlled study subject PAH currently receive approve therapy PAH ( i.e. , endothelin receptor antagonist and/or phosphodiesterase-5 inhibitor ) . Study visit occur 4 week interval 16 week key measure efficacy 6-minute walk test . Study procedure include routine blood test , medical history , physical exam , disease evaluation , exercise test . Patients complete assessment 16-weeks also eligible enter open-label , extension phase study ( FREEDOM - EXT ) .</brief_summary>
	<brief_title>Efficacy Safety Oral UT-15C Tablets Treat Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>A subject eligible inclusion study follow criterion apply : Between 18 75 year age , inclusive . Body weight least 40 kg ( approximately 90 lb . ) PAH either idiopathic/heritable ; associate appetite suppressant toxin use ; associate collagen vascular disease ; associate repair congenital shunt ; associate HIV . Currently receive approve endothelin receptor antagonist and/or approve phosphodiesterase5 inhibitor least 90 day stable dose least last 30 day . Baseline sixminute walk distance ( 6MWD ) 150425 meter Previous test ( e.g. , right heart catheterization , echocardiography ) consistent diagnosis PAH . Reliable cooperative protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>